Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapentadol

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Collegium Pharmaceutical

            Deal Size: $375.0 million Upfront Cash: $375.0 million

            Deal Type: Agreement February 06, 2020

            Details:

            Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.